Popular Articles
Teeth Whitening

Agennix Receives Fast Track Designation From FDA For Talactoferrin In Combination With Sunitinib For Renal Cell Carcinoma
Agennix announced that talactoferrin alfa (talactoferrin) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent(R) - Pfizer).
generic viagra online
New Drug Application For Exenatide Once Weekly Accepted For Review By FDA
Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA).
plastic surgery before after
News of the day
CareFusion Expands Pyxis(R) Perioperative Solutions Offering
CareFusion Corporation, the company that will become publicly traded following the planned spinoff of the clinical and medical products businesses of Cardinal Health, announced it has expanded its Pyxis® perioperative offerings that integrate with leading operating room information systems (ORIS), incorporate radio-frequency identification (RFID) technology1 and include new services.
Public Health

Type 1 Diabetes Cases In Children Under Five To Double By 2020

Cases of type 1 diabetes in children under five years across Europe will double by 2020 (from 2005 levels) if present trends continue. Numbers in children older than five will also increase substantially. The findings are discussed in an Article published Online First and in an upcoming edition of The Lancet, written by Dr Chris Patterson, Queen"s University, Belfast, UK, and Prof Gyula Soltç©sz, Pç©cs University, Pç©cs, Hungary, and colleagues. Type 1 diabetes is caused by insulin deficiency (and thus must be treated with insulin injections), whereas type 2 diabetes is caused by reduced insulin sensitivity along with some insulin deficiency. In the general population, type 1 diabetes cases represent only 10% of total diabetes cases. However among children the numbers of cases of type 1 diabetes is higher than type 2 in most countries. To predict the future burden of type 1 diabetes, the authors analysed diabetes data from 20 centres in 17 European countries, which had registered 29311 cases of type 1 diabetes during the period 1989-2003. The researchers found that the overall increase in incidence of type 1 diabetes was 3.9% per year; while the annual increase in the 0-4 years age group was 5.4%, with a 4.3% rise in the 5-9 years age group, and a 2.9% rise in 10-14-year-olds. There were estimated to have been approximately 15,000 new cases in Europe in 2005, divided among the 0-4 years, 5-9 years, and 10-14 in the ratio 24%, 37% and 34% respectively. A total of 24,400 new cases is predicted in 2020, with a doubling in the number of cases in children aged under 5 years and a more even distribution across age groups than at present (29%, 37%, and 34% respectively). If present trends continue, the total number of cases (new and existing) in European children under 15 years is predicted to rise from 94,000 in 2005 to 160,000 in 2020-a 70% increase. The changes over time are so rapid, say the authors, that they clearly cannot be because of genetic factors alone. They discuss modern lifestyle habits as possible contributory factors, such as increased weight and height development and increased caesarean section births. The higher increases are seen in Eastern Europe, where lifestyle habits are also changing more rapidly than in the richer European countries. The authors conclude: "The predicted rise in childhood type 1 diabetes in Europe during the next 20 years, and the raised proportion of cases diagnosed at younger ages than were before, could result in more cases presenting with ketoacidosis and needing hospital admission. More patients with severe diabetes complications presenting at younger ages than before are also likely, and appropriate care from diagnosis, and maintenance of good metabolic control are crucial for delay or prevention of these adverse complications. In the absence of any effective means to prevent type 1 diabetes, European countries need to ensure appropriate planning of services and that res are in place to provide high-quality care for the increased numbers of children who will be diagnosed with diabetes in future years." In an accompanying Comment, Dr Dana Dabelea, Colorado School of Public Health, University of Colorado, Denver, CO, USA, says the findings from this and other studies suggest "that the incidence of type 1 diabetes is increasing even faster than before, pointing towards harmful changes in the environment in which contemporary children live". She also discusses the findings specific to children under 5, and the concerns that younger age of onset of type 1 diabetes is usually associated with more acute symptoms. The consequences of longer exposure to altered metabolism due to diabetes and the increasing economic costs of the disease are also looked at. She concludes: "It is imperative that efforts directed at surveillance of diabetes in young people continue and expand, not only to understand its complex aetiology, but also because of its increasing public health importance." Link to article The Lancet


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):